An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease.
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2012
At a glance
- Drugs FX 125L (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 26 Apr 2012 Official Title amended, primary endpoints added and planned number of patients (119) added as reported by European Clinical Trials Database.
- 26 Apr 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2011-005036-26).
- 26 Apr 2012 Status changed from planning to recruiting as reported by European Clinical Trials Database.